Clinical Trials Directory

Trials / Completed

CompletedNCT00295555

Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy

Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
98 (actual)
Sponsor
Yokohama City University Medical Center · Academic / Other
Sex
All
Age
20 Years – 79 Years
Healthy volunteers
Not accepted

Summary

Few studies have reported the effect of alpha1-adrenergic antagonists on 24-h blood pressure and regulation of sympathetic nervous activity in hypertensive patients with diabetic nephropathy. Using ambulatory blood pressure monitoring devices equipped with spectral analysis of heart rate variability, we assess the effects of doxazosin on blood pressure in diabetic nephropathy patients and compare the results with those in patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy.

Detailed description

The study is an open-labeled parallel prospective trial comparing the effects of doxazosin (2-8 mg/day) on 24-h blood pressure and autonomic nervous activity. Hypertensive patients with non-insulin-dependent diabetic nephropathy, patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy undergo ambulatory blood pressure monitoring before and after treatment with doxazosin. Simultaneously, spectral analysis is performed to calculate the high frequency components as a marker of parasympathetic nervous activity, and the low frequency components/high frequency components ratios as an index of the sympathovagal balance.

Conditions

Interventions

TypeNameDescription
DRUGEffects of doxazosin on morning surge in diabetic patients

Timeline

Start date
2004-01-01
Completion
2007-04-01
First posted
2006-02-23
Last updated
2007-05-10

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT00295555. Inclusion in this directory is not an endorsement.